[Tirofiban improved the prognosis of senior acute coronary syndrome patients received percutaneous coronary intervention].

To examine if tirofiban may improve the prognosis in aged acute coronary syndrome (ACS) patients received percutaneous coronary intervention (PCI).
Three hundred and twenty-five ACS patients (age ≥ 60 years), all received drug-eluting stents implantation, were assigned into tirofiban group (n = 210) to receive tirofiban+aspirin and clopidogrel and control group (n = 115) to received aspirin and clopidogrel only. The incidence of thrombolysis in myocardial infarction (TIMI) grade 3 after PCI, in-stent thrombosis, slight/severe bleeding, platelet decrease, myocardial infarction (MI) and target vessel revascularization (TVR) within 30 days and 12 months after PCI and 30 days and 12 months mortality post PCI.
In comparison with the control group, the tirofiban group had significantly higher TIMI grade 3 flow after PCI (99.05% vs. 94.78%, P < 0.05), lower in-stent thrombosis (0.47% vs. 2.61%, P < 0.05), as well as lower mortality, MI, and TVR in 30 days and 12 months after PCI (30 days: 0, 0.47% and 0.47% vs. 2.61%, 3.48% and 2.61%; 12 months: 0, 0.47% and 0.47% vs. 2.61%, 5.22% and 5.22%, P < 0.05 or P < 0.01). No significant difference was found (both P > 0.05) in slight bleeding (7.14% vs. 4.35%) and severe bleeding (0 vs. 0) between tirofiban group and control group. A slight difference in thrombocytopenia was found between tirofiban group and control group (0.95% vs. 0), but it failed to reach the level of statistical significance (P > 0.05).
Tirofiban may improve the TIMI grade flow in senior ACS patients after PCI. It also decreases the incidence of in-stent thrombosis, mortality, MI, and TVR in 30 days and 12 months after PCI, without causing increase in severe bleeding and platelet penia. Therefore, it may improve the short/long-term prognosis for these patients.
AuthorsYu-xiao Zhang, Cai-yi Lu, Sheng-hua Zhou, Qiao Xue, Lei Gao, Jin-wen Tian, Wei Gao, Rui Chen, Jin-Yue Zhai, Li-Jun Li
JournalZhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue (Zhongguo Wei Zhong Bing Ji Jiu Yi Xue) Vol. 23 Issue 12 Pg. 727-30 (Dec 2011) ISSN: 1003-0603 [Print] China
PMID22153009 (Publication Type: Controlled Clinical Trial, English Abstract, Journal Article)
Chemical References
  • Platelet Aggregation Inhibitors
  • Tyrosine
  • clopidogrel
  • tirofiban
  • Ticlopidine
  • Aspirin
  • Acute Coronary Syndrome (therapy)
  • Aged
  • Angioplasty, Balloon, Coronary (methods)
  • Aspirin (therapeutic use)
  • Female
  • Humans
  • Male
  • Middle Aged
  • Platelet Aggregation Inhibitors (therapeutic use)
  • Prognosis
  • Ticlopidine (analogs & derivatives, therapeutic use)
  • Tyrosine (analogs & derivatives, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: